TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07681882: A Phase 1, Multicenter, Open-label, First-in-Human Trial of DS1025a in Participants With Advanced Solid Tumors

Sponsor: Daiichi Sankyo · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 45 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$5,560,632

Rescue Site Savings

+$3,675,672

Unlock Full NCT07681882 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07681882 Rescue Dossier →